| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10007628 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10012925 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10002101 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10002102 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10023157 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10029289 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10023156 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10029290 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10041980 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
| TVIS10052811 | HBV | ENSG00000157388.20 | protein_coding | CACNA1D | Yes | No | 776 | A0A1B0GUN6 Q01668 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CACNA1D |
|---|---|
| DrugBank ID | DB00393 |
| Drug Name | Nimodipine |
| Target ID | BE0002359 |
| UniProt ID | Q01668 |
| Regulation Type | inhibitor |
| PubMed IDs | 19029287; 20334460; 20335610; 19844625; 20661350; 17705883 |
| Citations | Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24.@@Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405.@@Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24.@@Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30.@@Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652.@@Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. |
| Groups | Approved; Investigational |
| Direct Classification | Dihydropyridinecarboxylic acids and derivatives |
| SMILES | COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C |
| Pathways | Nimodipine Action Pathway |
| PharmGKB | PA450633 |
| ChEMBL | CHEMBL1428 |
